8-K filed May 8, 2026, 7:59 PM ET ticker INBP CIK 0001016504

earnings confidence high sentiment negative materiality 0.75

Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

INTEGRATED BIOPHARMA INC

2026-Q3 EPS reported -$0.05 revenue$34,076,000

Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.
Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.
Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).
Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year).

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-26-015928
form_type: 8-K
ticker: INBP
cik: 0001016504
company_name: INTEGRATED BIOPHARMA INC
filed_at: 2026-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.804402+00:00
generated_at: 2026-05-14T19:28:50.316859+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-26-015928
json_url: https://secwatch.observer/filing/0001437749-26-015928.json
markdown_url: https://secwatch.observer/filing/0001437749-26-015928.md
text_url: https://secwatch.observer/filing/0001437749-26-015928.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/inbp20260507_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

099667fbc62a114f1c1a95695bfbcfa62b1d5054

INTEGRATED BIOPHARMA INC reported nine months ended March 31, 2026 results: revenue $34.1 million, net income net loss of $1.5 million, EPS $(0.05).

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

SEC 8-K Item 2.02 confidence 0.99 SEC evidence

f12a2b6e7595b51cc6d9edb2f5f53be62ff81984

INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2026 results: revenue $10.1 million, net income net loss of $0.8 million, EPS $(0.03).

BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March

SEC 8-K Item 2.02 confidence 0.98 SEC evidence

Comparable filings

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

DAVEY TREE EXPERT CO

Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M

DAVEY TREE EXPERT CO June 1, 2026, 1:50 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

Exchange Act, unless such subsequent filing specifically references this Form 8-K. --- EX-99.1 (EX-99.1) --- To Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue

Filing page SEC filing

DXYN

Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%

DIXIE GROUP INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000

Filing page SEC filing

SNDA

Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition

SONIDA SENIOR LIVING, INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.

Filing page SEC filing

URG

Ur-Energy Q1 2026: pounds captured up 41% QoQ, avg price $70.98, Shirley Basin commenced

UR-ENERGY INC May 11, 2026, 7:59 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

a 14% increase over Q4 2025 and a 13% increase over Q1 2025. Financial Performance ◾ Contracted Sales: We sold 55,000 produced pounds of U 3 O 8 as anticipated, generating $3.9 million in revenue, with a majority of our 2026 deliveries scheduled for the latter part of the year to complement the ramp-up and start-up schedules of Lost Creek and Shirley Basin. ◾

Filing page SEC filing

ACH

Accendra Health Q1 revenue $627.8M, adj. EBITDA $58.4M; >$1.5B debt optimization

ACCENDRA HEALTH INC/VA/ May 11, 2026, 7:59 PM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

Commission this morning. Details on First Quarter 2026 Results First Quarter Results (1) ($ in millions, except per share data) 1Q26 1Q25 Net Revenue $ 627.8 $ 673.9 Loss from continuing operations, net of tax, GAAP $ (6.5) $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP $ (3.1) $ 23.2

Filing page SEC filing

LQDA

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended

Comparable filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

Filing page SEC filing

Source: SEC EDGAR

accession 0001437749-26-015928

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.